Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application

DUBLIN, Aug. 21, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for ulipristal acetate (UPA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news